$6.42
10.69% today
Nasdaq, Feb 28, 05:24 pm CET
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Septerna Stock price

$5.80
-10.36 64.11% 1M
-12.20 67.78% 6M
-17.10 74.67% YTD
-12.20 67.78% 1Y
-12.20 67.78% 3Y
-12.20 67.78% 5Y
-12.20 67.78% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.10 1.75%
ISIN
US81734D1046
Symbol
SEPN
Sector
Industry

Key metrics

Market capitalization $257.54m
Enterprise Value $376.40m
P/B ratio (TTM) P/B ratio negative
Cash position $130.53m
P/E forward negative
P/S forward 352.02
EV/Sales forward 517.33

Is Septerna a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Septerna Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Septerna forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Septerna forecast:

Buy
75%
Hold
25%

Financial data from Septerna

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.18 0.18
500% 500%
100%
- Direct Costs 0.36 0.36
57% 57%
200%
-0.19 -0.19
5% 5%
-106%
- Selling and Administrative Expenses 4.17 4.17
79% 79%
2,317%
- Research and Development Expense 18 18
92% 92%
9,906%
-22 -22
88% 88%
-12,328%
- Depreciation and Amortization 0.36 0.36
57% 57%
200%
EBIT (Operating Income) EBIT -23 -23
87% 87%
-12,528%
Net Profit -21 -21
87% 87%
-11,400%

In millions USD.

Don't miss a Thing! We will send you all news about Septerna directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Septerna Stock News

Neutral
GlobeNewsWire
2 days ago
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.
Neutral
GlobeNewsWire
7 days ago
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN) on behalf of Septerna stockholders. Our investigation concerns whether Septerna has violated the federal securities laws and/or engaged in other unlawful business practices.
Neutral
GlobeNewsWire
9 days ago
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN). The investigation concerns whether Septerna and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
More Septerna News

Company Profile

Septerna, Inc. is a clinical-stage biotechnology company, which engages in pioneering a new era of G protein-coupled receptor oral small molecule drug discovery powered by proprietary Native Complex PlatformTM. Its pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. The company was founded by Robert Joseph Lefkowitz, Arthur Christopoulos, Patrick Sexton, and Jeffrey T. Finer in December 2019 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jeffrey Finer
Website www.septerna.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today